Literature DB >> 17967717

Inflammatory molecules: a target for treatment of systemic autoimmune diseases.

A Tincani1, L Andreoli2, C Bazzani2, D Bosisio3, S Sozzani3.   

Abstract

Inflammation is a process to protect the host against infection and danger signals. However, many pathologic conditions, including autoimmune diseases, are sustained by perpetual activation of the inflammatory process. In the past few years our knowledge about the molecular basis of inflammation have been uncovered and now much is known about the primary role of pro-inflammatory cytokines such as IL-1 and TNF. In the early '90s, anti-cytokine therapies started and confirmed the primary role of TNF in autoimmune diseases, such as rheumatoid arthritis, Crohn's Disease and psoriasis. Increasing understanding of the role of inflammatory mediators in inflammation and diseases is opening new avenues for the treatment of inflammatory-based diseases through selective targeting of cytokines and lipid mediators.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17967717     DOI: 10.1016/j.autrev.2007.03.001

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  17 in total

Review 1.  Infections and the antiphospholipid syndrome.

Authors:  Mario García-Carrasco; Claudio Galarza-Maldonado; Claudia Mendoza-Pinto; Ricardo O Escarcega; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 2.  Mycobacterium tuberculosis, autoimmunity, and vitamin D.

Authors:  Yinon Shapira; Nancy Agmon-Levin; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

3.  Tumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of uveitis.

Authors:  T K Khera; D A Copland; J Boldison; P J P Lait; D E Szymkowski; A D Dick; L B Nicholson
Journal:  Clin Exp Immunol       Date:  2012-05       Impact factor: 4.330

4.  A molecular mechanism for TNF-α-mediated downregulation of B cell responses.

Authors:  Daniela Frasca; Maria Romero; Alain Diaz; Sarah Alter-Wolf; Michelle Ratliff; Ana Marie Landin; Richard L Riley; Bonnie B Blomberg
Journal:  J Immunol       Date:  2011-11-23       Impact factor: 5.422

Review 5.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

6.  Metastatic-promoting effects of LPS: sexual dimorphism and mediation by catecholamines and prostaglandins.

Authors:  Ranit Naor; Vered Domankevich; Shaily Shemer; Luba Sominsky; Ella Rosenne; Ben Levi; Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2008-10-08       Impact factor: 7.217

7.  Changes in colon gene expression associated with increased colon inflammation in interleukin-10 gene-deficient mice inoculated with Enterococcus species.

Authors:  Matthew P G Barnett; Warren C McNabb; Adrian L Cookson; Shuotun Zhu; Marcus Davy; Bianca Knoch; Katia Nones; Alison J Hodgkinson; Nicole C Roy
Journal:  BMC Immunol       Date:  2010-07-15       Impact factor: 3.615

Review 8.  Novel mechanisms of action of the biologicals in rheumatic diseases.

Authors:  Cecilia Beatrice Chighizola; Ennio Giulio Favalli; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

Review 9.  A novel assay to measure B cell responses to keyhole limpet haemocyanin vaccination in healthy volunteers and subjects with systemic lupus erythematosus.

Authors:  John Ferbas; Shelley S Belouski; Michelle Horner; Arunan Kaliyaperumal; Li Chen; Malcolm Boyce; C Bernie Colaço; Neil McHugh; Vanessa Quick; Richard J Nicholl; Gerald Siu; James Chung
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

10.  Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis.

Authors:  Stacy M Plum; Eun J Park; Steve J Strawn; Elizabeth G Moore; Carolyn F Sidor; William E Fogler
Journal:  BMC Musculoskelet Disord       Date:  2009-05-01       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.